Long-lasting complete remission in a patient with systemic metastases of recurrent breast cancer treated with cyclin-dependent kinases 4/6 inhibitors: a case report
Abstract Background The prognosis for recurrence cases of hormone receptor-positive HER2-negative breast cancer remains poor, and treatment strategies that emphasize quality of life have often been chosen, with few physicians aiming for a cure. Our objective is to assess the validity of such current...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-05-01
|
| Series: | Journal of Medical Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13256-023-03902-4 |
| _version_ | 1797827515919630336 |
|---|---|
| author | Toshihiko Yoneto Kenichiro Hasumi Nobukazu Takahashi Nastuki Seki Yasutaka Takeda Takayuki Yoshimoto |
| author_facet | Toshihiko Yoneto Kenichiro Hasumi Nobukazu Takahashi Nastuki Seki Yasutaka Takeda Takayuki Yoshimoto |
| author_sort | Toshihiko Yoneto |
| collection | DOAJ |
| description | Abstract Background The prognosis for recurrence cases of hormone receptor-positive HER2-negative breast cancer remains poor, and treatment strategies that emphasize quality of life have often been chosen, with few physicians aiming for a cure. Our objective is to assess the validity of such current treatment strategies. Case presentation A 74-year-old Asian woman with multiple lung and liver metastases after local recurrence of breast cancer was treated with two different cyclin-dependent kinases 4/6 inhibitors sequentially in combination with endocrine therapy. Flow cytometric analysis of the patient’s peripheral blood mononuclear cells was also performed to evaluate the host’s immune status. Complete remission was achieved without cytotoxic agents and the patient remains disease free to this day, 6 years after the initial relapse. Additionally, no increase in the population of the immunosenescent T cells with a phenotype of CD8+CD28− was observed in the patient’s peripheral blood mononuclear cells, suggesting that the immune system was well maintained. Conclusions We present this case study to develop new treatment strategies for recurrent breast cancer that is not only bound to misinterpretations of the Hortobagyi algorithm, but also aim for a cure with noncytotoxic agents to maintain the host’s immune system and early detection of recurrence. |
| first_indexed | 2024-04-09T12:49:34Z |
| format | Article |
| id | doaj.art-8651e92bea6c4add834c95c609cef00a |
| institution | Directory Open Access Journal |
| issn | 1752-1947 |
| language | English |
| last_indexed | 2024-04-09T12:49:34Z |
| publishDate | 2023-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Medical Case Reports |
| spelling | doaj.art-8651e92bea6c4add834c95c609cef00a2023-05-14T11:18:01ZengBMCJournal of Medical Case Reports1752-19472023-05-011711610.1186/s13256-023-03902-4Long-lasting complete remission in a patient with systemic metastases of recurrent breast cancer treated with cyclin-dependent kinases 4/6 inhibitors: a case reportToshihiko Yoneto0Kenichiro Hasumi1Nobukazu Takahashi2Nastuki Seki3Yasutaka Takeda4Takayuki Yoshimoto5Department of Breast Surgery, Hijirigaoka Hospital, Tama CityDepartment of Breast Surgery, Hijirigaoka Hospital, Tama CityDepartment of Surgery, Oguchihigashi General HospitalDepartment of Breast Surgery, Hijirigaoka Hospital, Tama CityBreast Oncology Center, Fukujuji HospitalDepartment of Immunoregulation, Institute of Medical Science, Tokyo Medical UniversityAbstract Background The prognosis for recurrence cases of hormone receptor-positive HER2-negative breast cancer remains poor, and treatment strategies that emphasize quality of life have often been chosen, with few physicians aiming for a cure. Our objective is to assess the validity of such current treatment strategies. Case presentation A 74-year-old Asian woman with multiple lung and liver metastases after local recurrence of breast cancer was treated with two different cyclin-dependent kinases 4/6 inhibitors sequentially in combination with endocrine therapy. Flow cytometric analysis of the patient’s peripheral blood mononuclear cells was also performed to evaluate the host’s immune status. Complete remission was achieved without cytotoxic agents and the patient remains disease free to this day, 6 years after the initial relapse. Additionally, no increase in the population of the immunosenescent T cells with a phenotype of CD8+CD28− was observed in the patient’s peripheral blood mononuclear cells, suggesting that the immune system was well maintained. Conclusions We present this case study to develop new treatment strategies for recurrent breast cancer that is not only bound to misinterpretations of the Hortobagyi algorithm, but also aim for a cure with noncytotoxic agents to maintain the host’s immune system and early detection of recurrence.https://doi.org/10.1186/s13256-023-03902-4Breast cancerCDK4/6 inhibitorsComplete remissionImmune systemsImmunosenescent T cellRecurrence |
| spellingShingle | Toshihiko Yoneto Kenichiro Hasumi Nobukazu Takahashi Nastuki Seki Yasutaka Takeda Takayuki Yoshimoto Long-lasting complete remission in a patient with systemic metastases of recurrent breast cancer treated with cyclin-dependent kinases 4/6 inhibitors: a case report Journal of Medical Case Reports Breast cancer CDK4/6 inhibitors Complete remission Immune systems Immunosenescent T cell Recurrence |
| title | Long-lasting complete remission in a patient with systemic metastases of recurrent breast cancer treated with cyclin-dependent kinases 4/6 inhibitors: a case report |
| title_full | Long-lasting complete remission in a patient with systemic metastases of recurrent breast cancer treated with cyclin-dependent kinases 4/6 inhibitors: a case report |
| title_fullStr | Long-lasting complete remission in a patient with systemic metastases of recurrent breast cancer treated with cyclin-dependent kinases 4/6 inhibitors: a case report |
| title_full_unstemmed | Long-lasting complete remission in a patient with systemic metastases of recurrent breast cancer treated with cyclin-dependent kinases 4/6 inhibitors: a case report |
| title_short | Long-lasting complete remission in a patient with systemic metastases of recurrent breast cancer treated with cyclin-dependent kinases 4/6 inhibitors: a case report |
| title_sort | long lasting complete remission in a patient with systemic metastases of recurrent breast cancer treated with cyclin dependent kinases 4 6 inhibitors a case report |
| topic | Breast cancer CDK4/6 inhibitors Complete remission Immune systems Immunosenescent T cell Recurrence |
| url | https://doi.org/10.1186/s13256-023-03902-4 |
| work_keys_str_mv | AT toshihikoyoneto longlastingcompleteremissioninapatientwithsystemicmetastasesofrecurrentbreastcancertreatedwithcyclindependentkinases46inhibitorsacasereport AT kenichirohasumi longlastingcompleteremissioninapatientwithsystemicmetastasesofrecurrentbreastcancertreatedwithcyclindependentkinases46inhibitorsacasereport AT nobukazutakahashi longlastingcompleteremissioninapatientwithsystemicmetastasesofrecurrentbreastcancertreatedwithcyclindependentkinases46inhibitorsacasereport AT nastukiseki longlastingcompleteremissioninapatientwithsystemicmetastasesofrecurrentbreastcancertreatedwithcyclindependentkinases46inhibitorsacasereport AT yasutakatakeda longlastingcompleteremissioninapatientwithsystemicmetastasesofrecurrentbreastcancertreatedwithcyclindependentkinases46inhibitorsacasereport AT takayukiyoshimoto longlastingcompleteremissioninapatientwithsystemicmetastasesofrecurrentbreastcancertreatedwithcyclindependentkinases46inhibitorsacasereport |